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Abstract We present the case of a 29-year-old woman who developed a severe hypothyroid-
ism induced by a thyroxine malabsorption and a secondary pituitary hyperplasia. 
We performed thyroxine absorption tests to diagnose the malabsorption and to 
evaluate the best therapeutic intervention. Once assessed a correct therapy lower-
ing TSH, we observed the regression of pituitary mass confirming our diagnosis 
of secondary pituitary hyperplasia. We suggest to evaluate any possible reason for 
thyroxine malabsorption and to consider the hypothesis of pituitary hyperplasia 
in the presence of pituitary mass together with overt hypothyroidism. 
Abbreviations: 
TRT - thyroid hormone therapy 
TSH - thyroid stimulating gland
TRH - thyroid releasing hormone
FT4 - free L-thyroxine
FT3 - free L-triiodothyronine
MRI - magnetic resonance imaging
L-T4 - L-thyroxine
L-T3 - L-triiodothyronine
EGDS - esophagogastroduodenoscopy
INTRODUCTION
In the endocrine practice hypothyroidism result-
ing from different pathological conditions is highly 
prevalent (Jonklaas et al. 2014). In most patients, 
administration of thyroid hormone therapy (TRT) 
completely resolves hypothyroidism in few weeks. 
Replacement dose of 1.6 μg/kg/die L-T4 represents 
an adequate replacement for most adults, whereas 
higher dose are necessary in newborns and in 
children (Vaidya & Pearce 2008; Leger et al. 2014; 
Wiersinga 2001). Recent guidelines recommend 
the use of L-T4 for TRT, even if combination of 
L-T4 and L-T3 represents an option in patients 
who remain symptomatic despite the normaliza-
tion of TSH, FT4 and FT3 and in those patients 
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with metabolic dysfunction, such as impaired function 
of deiodinase 1 and 2 (Okosieme et al. 2016). Rarely, 
physicians may have to face the failure of TRT due to 
a malabsorption leading to overt hypothyroidism. A 
severe hypothyroidism may cause a marked TSH eleva-
tion due to an increase in TRH secretion. The absence 
of thyroxine feedback inhibition on hypothalamus and 
on pituitary gland may induce a process of pituitary 
hyperplasia mimicking macroadenoma (Namburi et 
al. 2014; Agrawal & Diwan 2011; Rajput et al. 2012). 
Even the most advanced imaging techniques (i.e. CT 
and MR scan) may not distinguish between adenoma 
and hyperplasia of pituitary thyrotrophic cells; defini-
tive diagnosis is established following TRT, as pituitary 
hyperplasia responds to TRT whereas adenoma does 
not.
CASE REPORT
A 29-year-old woman presented to our attention with 
complaint of severe asthenia, weight gain, hypercholes-
terolemia and oligoamenorrhea. 
Her medical history was unremarkable except for 
chronic autoimmune thyroiditis (TPO Ab 334 IU/ml, 
normal 0–50 IU/ml) and hypothyroidism (FT4 0.32 
ng/dL, normal 0.61–1.12 ng/dL; TSH 150 μIU/mL, 
normal 0.34–5.6 μIU/mL) diagnosed at age of 19. The 
patient was then started on 50 μg/d of L-T4 in tablet 
form, on empty stomach in the morning. On follow up 
after 12 weeks, TSH was not yet in normal range and 
L-T4 was gradually raised to 150 μg/d (2.9 μg/kg/die) 
over the course of 20 weeks. After  5 weeks of treat-
ment with 150 μg/d, thyroid function test revealed 
TSH 0.65 mU/ml (normal 0.5–4.0 mU/ml), FT3 4.14 
pg/ml (normal 1.5–4.5 pg/ml) FT4 1.7 ng/dl (normal 
0.75–1.95 ng/dl). Her weight was stable at 50 kg and a 
regular menstrual cycle was observed. Yearly follow-up 
was then performed.
Ten years later an increase in body weight of eight 
kilograms was observed despite no change in lifestyle; 
a blood test revealed TSH 665.5 mU/ml (normal 0.5–
4.0 mU/ml), FT3 1.0 pg/ml (normal 1.5–4.5 pg/ml) and 
FT4 0.1 ng/dl (normal 0.75–1.95 ng/dl). L-T4 therapy 
was substituted with combination therapy consisting 
in L-T4 50 μg/die in liquid form and L-T3 20 μg bid 
in liquid form(Biondi & Wartofsky 2012). At the same 
time, eye fundus examination and brain MRI were 
performed at the request of a neurologist following a 
perceived loss of peripheral vision and frequent head-
aches, unresponsive to pharmacological treatment. Eye 
fundus examination showed papilledema and a signifi-
cant impairment of visual field limited to the left eye. 
MRI showed a pituitary enlargement and revealed in 
left pituitary lobe 11×8×7 mm mass, intensely enhanced 
following gadolinium injection, without any elevation 
of the optic chiasm and of the pituitary stalk. This mass 
was reported to be suggestive of a pituitary macroad-
enoma by radiologists (Figure 1).
In the suspect of a pituitary adenoma we performed 
further blood analysis of pituitary function including: 
prolactin, GH, IGF-1, FSH, LH, ACTH and cortisol. 
Blood test results showed a slight increase of prolactin 
(30.0 ng/ml, normal 5–27 ng/ml) ascribed to either 
TRH increase or to stress reaction to blood draw. On the 
A B
Fig. 1. Initial pituitary Gd-DTPA enhanced MRI revealing pituitary left lobe enlargement. (A) Enhanced coronal image. (B) Enhanced sagittal image. 
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base of the clinical features and of the blood test results 
it was possible to rule out the pituitary TSH adenoma, 
suggesting a case of thyreotropic cell hyperplasia as the 
secondary etiology of the pituitary mass. Meanwhile 
oligoamenorrhea occurred, and complete recovery of 
menstrual function was observed in about six months 
with menstrual cycle length of about 32 days.
Since the patient was not responsive to a high dosage 
combination therapy, a gastrointestinal origin of mal-
absorption was suspected. An EGDS with multiple 
biopsies, a fecal parasitological test and urea breath 
test for lactose intolerance were performed with nega-
tive results. Urea breath test for helicobacter pylori was 
positive and triple therapy was started. Two months 
later the follow-up urea breath test was negative. On 
follow up after 8 weeks, the blood test showed overt 
hypothyroidism (TSH 542.83 mU/ml, FT3 1.28 pg/ml 
and FT4 0.1 ng/dl).
Being a selective L-T4 malabsorption suspected, a 
three hours LT4 oral loading test was performed, show-
ing a continuous increase of FT4 in the bloodstream 
(Figure 2). A six hours L-T4 oral load was subsequently 
performed, revealing a peak absorption time at fourth 
hour (Figure 3). 
Both oral L-T4 load tests revealed a low and delayed 
serum peak concentration of free thyroid hormones. 
Consequently therapy was gradually raised to L-T4 
400 μg/die in soft gel capsule administered five hours 
before any food intake and thyroid test showed TSH 
2.53 mU/ml (0.35–4.95 mU/ml), FT4 1.19 ng/dl (0.70–
1.50 ng/dl), FT3 3.03 pg/ml (1.7–3.7 pg/ml).
A follow-up MRI scan was performed revealing a 
significant shrinkage of pituitary gland to 6 mm, homo-
geneously enhanced without any circumscribed lesion, 
confirming our diagnostic hypothesis of thyrotropic 
pituitary hyperplasia (Figure 4).
DISCUSSION
The majority of hypothyroid patients responds well to 
TRT; nevertheless, malabsorption of L-thyroxine is one 
of the most common issue during TRT, as many drugs 
may interfere with its absorption such as: calcium car-
bonate, cholestyramine, colesevelam, ferrous sulfate, 
proton pump inhibitors, aluminum-containing antacid, 
cation-exchange resin, sucralfate, raloxifene, orlistat, 
phosphate binders, coffee, soy, dietary fiber, grapefruit 
juice (Singh et al. 2000; Liwanpo & Hershman 2009; 
Campbell et al. 1992; Sachmechi et al. 2007; McLean et 
al. 1993; Campbell et al. 1994; Siraj et al. 2003; Madhava 
& Hartley 2005; Benvenga et al. 2008; Bell & Ovalle 
2001; McMillan et al. 2016; Lilja et al. 2005).
Furthermore, adequate gastric acid secretion is 
required for tablet TRT. Indeed, tablet L-T4 is admin-
istered on empty stomach, 30–60 minutes before 
any food, as assumption of food increases gastric pH 
decreasing L-T4 tablet dissolution(Sachmechi et al. 
2007). Absorption of L-T4 may be negatively affected 
by different pathological conditions such as autoim-
mune atrophic gastritis, Helicobacter pylori infection, 
lactose intolerance, celiac disease, inflammatory bowel 
disease, bowel resection, Giardia infection (McMil-
lan et al. 2016; Centanni et al. 2006; Cellini et al. 2014; 
Zubarik et al. 2015; Seppel et al. 1996; Vinagre & Souza 
2011).
Recently, the introduction of L-T4 in liquid form and 
in soft gel decreased the cases of L-T4 malabsorption as 
these pharmacological preparations do not require an 
acidic gastric environment and do not contain lactose 
(Virili et al. 2016; Vita et al. 2013).
However, despite using high doses of L-T4 in soft 
gel, our patient remained hypothyroid with high levels 
of TSH. We excluded poor adherence to therapy, all 
the pathological causes of LT-4 malabsorption and all 
the possible drug interactions. Oral L-T4 load test per-
formed twice showed a delayed and reduced increase 
in serum FT4 and FT3 levels, suggesting a selective 
malabsorption. We opted for increasing daily dose of 
L-T4 in soft gel till 400 μg/die administered on empty 
stomach at 6.00 a.m. five hours before consuming the 
first meal. In such a way, we observed a gradual rise in 
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Fig. 2. Graph shows a delayed but continuous increase of both 
serum Ft4 and Ft3 after 180 minutes.
Fig. 3. Graph shows a limited and delayed absorption of L-T4, with a 
peak serum concentrations of both FT3 and FT4 at 240 minutes 
after the oral load.
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serum level FT4 and FT3 and a decrease in TSH levels 
till the definitive normalization of each parameter.
In our patient severe hypothyroidism resulted in 
hyperplasia of thyrotroph cells due to the lack of nega-
tive feedback of thyroid hormones on hypothalamus 
with subsequent increase of TRH and of TSH values. 
Hyperplasia represents a reversible process occurring in 
response to a physiological increase in pituitary stimu-
lation (Ashley et al. 2005; Lee et al. 2008). However, 
despite the significant improvements in cerebral imag-
ing it’s not possible to distinguish pituitary macroad-
enoma from hyperplasia; nevertheless, we excluded the 
hypothesis of TSH-adenoma considering the clinical 
and biochemical signs of hypothyroidism. The diag-
nosis of secondary pituitary hyperplasia was then con-
firmed by the regression of the pituitary mass after the 
normalization of TSH values.
The normalization of TSH caused also a decrease of 
serum prolactin level and in few months normal men-
strual cycle occurred.
CONCLUSION
We advised to evaluate any pituitary mass accompanied 
by high serum TSH values and low thyroid hormones 
considering the diagnosis of thyrotrophic pituitary 
hyperplasia. Adequate TRT may solve the problem even 
in the case of selective L-T4 malabsorption. In such a 
case a L-T4 absorption test is recommended to evaluate 
the pathology leading to the best treatment option.
Informed consent: Informed consent was obtained from 
the patient included in the study
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